XenoTherapeutics to acquire Repare Therapeutics in all-cash deal

CAMBRIDGE — Repare Therapeutics Inc (RPTX.O), a clinical-stage precision oncology firm, said on Saturday it has agreed to be acquired by nonprofit biotech XenoTherapeutics Inc and its affiliate Xeno Acquisition…

NNR November 15, 2025

London Stock Exchange

Avacta Group raises £16 million in equity fundraise, extends cash runway

LONDON: British biopharmaceutical company Avacta Group Plc (AVCT.L) said on Monday it has raised approximately £16 million ($20.5 million) in an oversubscribed share placing, providing it with working capital to…

NNR October 20, 2025

Wire

Johnson & Johnson to spin off orthopedics unit named DePuy Synthes

NEW BRUNSWICK: Johnson & Johnson said Tuesday it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its…

NNR October 14, 2025

London Stock Exchange

Luke Miels appointed CEO designate for GSK

LONDON: GSK plc (LSE/NYSE: GSK) today announced that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026.…

Bernice Miles September 29, 2025

London Stock Exchange

Roquefort Therapeutics to acquire Coiled Therapeutics in £30 million reverse takeover

LONDON: Roquefort Therapeutics plc (LSE:ROQ), a Main Market-listed biotech firm, said Monday it has entered into a binding term sheet to acquire Coiled Therapeutics, Inc., a clinical-stage oncology company spun…

NNR September 8, 2025

Wire

Tempus AI acquires Paige to accelerate oncology AI innovation

CHICAGO: Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence-driven precision medicine, announced Friday it has acquired Paige, a digital pathology company known for pioneering FDA-cleared AI applications in…

NNR August 23, 2025

London Stock Exchange

GSK signals confidence with robust Q2 as specialty medicines surge

Operating profit up 33% as strong product mix and R&D drive gains GSK Plc reported another solid quarter in Q2 2025, underscoring its trajectory toward the top end of its…

Ali Mirza July 30, 2025

London Stock Exchange

GSK, China’s Hengrui Pharma ink $500m deal to co-develop 12 innovative medicines

LONDON: GSK plc announced Monday that it has entered into agreements with China-based Hengrui Pharma to co-develop up to 12 innovative medicines spanning respiratory, immunology, inflammation and oncology indications, marking…

Ali Mirza July 28, 2025

Wire

AstraZeneca reports strong growth in 2023 despite COVID-19 challenges

AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase in core earnings per share.…

NNR February 8, 2024

London Exchange

Jazz Pharmaceuticals acquires Redx’s KRAS inhibitor program

Alderley Park, UK: Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and…

Ali Mirza February 7, 2024

London Exchange

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment

LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate…

NNR July 27, 2020

Singapore Exchange

Avacta signs collaboration and option agreement with ADC Therapeutics

LONDON: Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with ADC Therapeutics SA (Lausanne, CH),…

NNR October 10, 2019